JAZZ
Jazz Pharmaceuticals PLC
240.70$
-1.3%
vs. previous close
Closing price · As of: Sep 18, 2026
Ownership
Ownership Structure
Who owns Jazz Pharmaceuticals PLC (JAZZ)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 97.0% of the shares are freely tradable; institutional investors hold 108.2%.
Institutional ownership
?Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings.
108.2%
Insiders
?Share of the stock held by the executives, founders and major shareholders of the company itself.
3.1%
Float
?Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders.
97.0%
Short % of float
?Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices.
7.3%
Shares Outstanding
?Total number of shares issued. Price times share count gives market cap.
65Mio.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| BlackRock Inc | 8.61 | 5,591,700 | +2.6 | 03/31/2026 |
| Vanguard Portfolio Management, LLC | 4.60 | 2,983,242 | +0.0 | 03/31/2026 |
| Capital World Investors | 4.16 | 2,697,610 | +0.9 | 06/30/2026 |
| Vanguard Capital Management, LLC | 4.08 | 2,648,333 | +0.0 | 03/31/2026 |
| FMR Inc | 3.51 | 2,275,762 | +184.1 | 03/31/2026 |
| LSV Asset Management | 3.50 | 2,275,145 | -4.7 | 06/30/2026 |
| Franklin Templeton Inc | 3.02 | 1,958,940 | +7.7 | 03/31/2026 |
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| iShares Core S&P Mid-Cap ETF | 3.38 | 2,197,199 | +0.0 | 08/31/2026 |
| American Funds Fundamental Invs A | 3.24 | 2,100,000 | +0.0 | 06/30/2026 |
| Capital Group Fundamental Invtrs Comp | 3.24 | 2,100,000 | +0.0 | 06/30/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Insider holdings
| Person | Role | Shares | Value | As of | Type |
|---|---|---|---|---|---|
| Mulligan Seamus | Director | 1,184,633 | 285,141,163 $ | Aug 5, 2026 | direct |
| Cozadd Bruce C | Director | 351,875 | 84,696,313 $ | Sep 1, 2026 | direct |
| Gala Renee D | President & CEO | 143,394 | 34,514,936 $ | Sep 8, 2026 | direct |
| Iannone Robert | EVP, Global Head of R&D & CMO | 65,686 | 15,810,620 $ | Aug 27, 2026 | direct |
| Patil Neena M | EVP & Chief Legal Officer | 47,671 | 11,474,410 $ | Sep 10, 2026 | direct |
| Pearce Samantha | EVP, Chief Commercial Officer | 47,131 | 11,344,432 $ | Aug 5, 2026 | direct |
| Henderson Mary Elizabeth | SVP, Technical Operations | 23,815 | 5,732,271 $ | Sep 8, 2026 | direct |
| Enright Patrick G | Director | 21,278 | 5,121,615 $ | Aug 31, 2026 | direct |
| McSharry Heather Ann | Director | 18,199 | 4,380,499 $ | Aug 31, 2026 | direct |
| Cook Jennifer E. | Director | 10,736 | 2,584,155 $ | Aug 31, 2026 | direct |
| Smith Mark Douglas | Director | 9,579 | 2,305,665 $ | Aug 31, 2026 | direct |
| Winningham Rick E | Director | 9,466 | 2,278,466 $ | Aug 31, 2026 | direct |
| Riedel Norbert G | Director | 6,923 | 1,666,366 $ | Aug 31, 2026 | direct |
| Hamill Laura | Director | 6,832 | 1,644,462 $ | Aug 31, 2026 | direct |
| Kennedy Patrick | Director | 6,452 | 1,552,996 $ | Aug 31, 2026 | direct |
Holdings as of each person's most recent SEC Form 4 filing — excluding options and RSUs, which are not shares yet. Holdings may have changed between two filings.
Insiders
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 10, 2026 | Patil Neena M | EVP & Chief Legal Officer | Sell | 1,200 | 240.94 | 289,128 |
| Sep 8, 2026 | Henderson Mary Elizabeth | SVP, Technical Operations | Other | 15 | 241.20 | 3,618 |
| Sep 8, 2026 | Henderson Mary Elizabeth | SVP, Technical Operations | Other | 1,412 | 243.03 | 343,158 |
| Sep 8, 2026 | Gala Renee D | President & CEO | Sell | 2,000 | 243.03 | 486,060 |
| Sep 8, 2026 | Gala Renee D | President & CEO | Other | 1,967 | 246.81 | 485,475 |
| Sep 1, 2026 | Cozadd Bruce C | Director | Sell | 6,000 | 250.13 | 1,500,780 |
| Aug 31, 2026 | Kennedy Patrick | Director | Other | 1,840 | 241.39 | 444,158 |
| Aug 31, 2026 | Kennedy Patrick | Director | Other | 15 | 244.06 | 3,661 |
| Aug 31, 2026 | Henderson Mary Elizabeth | SVP, Technical Operations | Other | 16 | 244.64 | 3,914 |
| Aug 31, 2026 | Henderson Mary Elizabeth | SVP, Technical Operations | Other | 2,076 | 241.39 | 501,126 |
| Aug 31, 2026 | Smith Mark Douglas | Director | Other | 1,692 | 241.39 | 408,432 |
| Aug 31, 2026 | Smith Mark Douglas | Director | Other | 14 | 244.64 | 3,425 |
| Aug 31, 2026 | Cook Jennifer E. | Director | Other | 1,692 | 241.39 | 408,432 |
| Aug 31, 2026 | Cook Jennifer E. | Director | Other | 14 | 244.06 | 3,417 |
| Aug 31, 2026 | Hamill Laura | Director | Other | 1,692 | 241.39 | 408,432 |
| Aug 31, 2026 | Hamill Laura | Director | Other | 14 | 244.06 | 3,417 |
| Aug 31, 2026 | McSharry Heather Ann | Director | Other | 1,840 | 241.39 | 444,158 |
| Aug 31, 2026 | McSharry Heather Ann | Director | Other | 15 | 244.64 | 3,670 |
| Aug 31, 2026 | Winningham Rick E | Director | Other | 14 | 244.64 | 3,425 |
| Aug 31, 2026 | Winningham Rick E | Director | Other | 1,692 | 241.39 | 408,432 |
| Aug 31, 2026 | Enright Patrick G | Director | Other | 1,692 | 241.39 | 408,432 |
| Aug 31, 2026 | Enright Patrick G | Director | Other | 14 | 244.64 | 3,425 |
| Aug 31, 2026 | Cozadd Bruce C | Director | Other | 1,209 | 241.39 | 291,840 |
| Aug 31, 2026 | Cozadd Bruce C | Director | Other | 10 | 244.06 | 2,441 |
| Aug 31, 2026 | Love Ted W | Director | Other | 737 | 241.39 | 177,904 |
| Aug 31, 2026 | Love Ted W | Director | Other | 6 | 244.06 | 1,464 |
| Aug 31, 2026 | Riedel Norbert G | Director | Other | 1,692 | 241.39 | 408,432 |
| Aug 31, 2026 | Riedel Norbert G | Director | Other | 14 | 244.64 | 3,425 |
| Aug 27, 2026 | Iannone Robert | EVP, Global Head of R&D & CMO | Sell | 300 | 252.76 | 75,828 |
| Aug 27, 2026 | Iannone Robert | EVP, Global Head of R&D & CMO | Sell | 9,259 | 251.95 | 2,332,804 |
| Aug 27, 2026 | Iannone Robert | EVP, Global Head of R&D & CMO | Sell | 19,639 | 250.60 | 4,921,596 |
| Aug 27, 2026 | Iannone Robert | EVP, Global Head of R&D & CMO | Sell | 18,113 | 250.02 | 4,528,572 |
| Aug 27, 2026 | Iannone Robert | EVP, Global Head of R&D & CMO | Sell | 11,423 | 248.67 | 2,840,516 |
| Aug 27, 2026 | Iannone Robert | EVP, Global Head of R&D & CMO | Sell | 18,187 | 247.86 | 4,507,781 |
| Aug 27, 2026 | Iannone Robert | EVP, Global Head of R&D & CMO | Other | 2,916 | 137.12 | 399,842 |
| Aug 27, 2026 | Iannone Robert | EVP, Global Head of R&D & CMO | Other | 27,584 | 137.12 | 3,782,318 |
| Aug 27, 2026 | Iannone Robert | EVP, Global Head of R&D & CMO | Other | 884 | 113.10 | 99,980 |
| Aug 27, 2026 | Iannone Robert | EVP, Global Head of R&D & CMO | Other | 26,116 | 113.10 | 2,953,720 |
| Aug 5, 2026 | Kennedy Patrick | Director | Other | 1,605 | 0.00 | – |
| Aug 5, 2026 | Pearce Samantha | EVP, Chief Commercial Officer | Other | 780 | 261.62 | 204,064 |
| Aug 5, 2026 | Smith Mark Douglas | Director | Other | 1,605 | 0.00 | – |
| Aug 5, 2026 | Cook Jennifer E. | Director | Other | 1,605 | 0.00 | – |
| Aug 5, 2026 | Hamill Laura | Director | Other | 1,605 | 0.00 | – |
| Aug 5, 2026 | McSharry Heather Ann | Director | Other | 1,605 | 0.00 | – |
| Aug 5, 2026 | Mulligan Seamus | Director | Other | 1,605 | 0.00 | – |
| Aug 5, 2026 | Winningham Rick E | Director | Other | 1,605 | 0.00 | – |
| Aug 5, 2026 | Enright Patrick G | Director | Other | 1,605 | 0.00 | – |
| Aug 5, 2026 | Cozadd Bruce C | Director | Other | 1,605 | 0.00 | – |
| Aug 5, 2026 | Love Ted W | Director | Other | 1,605 | 0.00 | – |
| Aug 5, 2026 | Riedel Norbert G | Director | Other | 1,605 | 0.00 | – |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character. View all insider transactions →
Data as of: September 18, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.